glp-1 receptor agonist and dpp-4 inhibitor combination contraindicated DPP4 Inhibitors vs Agonists | June 2021 | Clinical Corner Can patients be on both

Stiewig-Rapp is the incoming director of a new Obesity Clinic the health system is set to open in 2026

Nat Rev Nephrol 13 , 605628 (2017)

Univariately, no differences in 30% and 50% responder-rate were seen between the groups (Supplementary Table 1)

A recent 2025 study showed that participants who consumed 1 gram of berberine daily for 6 months had no meaningful change in adiposity (AKA the accumulation of body fat) 19

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

RCTs evaluating GLP-1 RA have not identified indicators of suicidality